The Use of Mephedrone (M-Cat, Meow) in Middlesbrough

Total Page:16

File Type:pdf, Size:1020Kb

The Use of Mephedrone (M-Cat, Meow) in Middlesbrough Mephedrone The Use of Mephedrone (M-cat, Meow) [ in Middlesbrough ] Dr. Russell Newcombe Senior Researcher, Lifeline Publications and Research Produced in December 2009 C o n t e n t s Executive Summary 3 1. Introduction 4 2. Research Methods 4 -5 3. Findings 5 -12 4. Conclusions 12-13 References 13 Appendices 14-16 Acknowledgments Thanks for help and assistance in conducting this report to: Andrea and Mandy (Lifeline Middlesbrough), and the ten people who participated in the three focus groups. Lifeline Publications and Research, 39-41 Thomas Street, Manchester M4 1NA. Telephone: 0161 8392075 E-mail: [email protected]. Web: www.lifeline.org.uk Lifeline is a registered charity No: 515691 2 Executive Summary . Mephedrone: the use of m-cat (Meow) in Middlesbrough Dr. Russell Newcombe Senior Researcher, Lifeline Publications & Research, Manchester; December 2009 ‘Legal highs’ are drugs which are not controlled The effects of mephedrone were regarded as both under the 1971 Misuse of Drugs Act nor licensed stimulant (like speed) and hallucinogenic (like for legal use. Mephedrone is a synthetic ‘legal high’ ecstasy or LSD). The full effects of one dose lasted manufactured from cathinone, the active ingredient around two to four hours. The main physical effects of the African shrub khat, and a natural analogue of mephedrone were reported to be nose-bleeds, of the stimulant drug amphetamine (speed/wiz). dilated pupils, blurred vision, dry mouth/thirst, hot Mephedrone is a white powder, and its full chemical flushes, fast/erratic heart-beats, muscular tension name is 4-methylmethcathinone (4MMC). It is in the jaw and limbs, and shrunken genitals (men known to users as meph and m-cat, and is sold by only). The main mental effects were initial ‘head headshops (in cities and on the internet) as plant rushes’, followed by euphoria, boundless energy, food under the trade name Meow. talkativeness, and time distortions – with heavier users also reporting visual hallucinations. The main In December 2009 Lifeline Publications & Research residual effect was insomnia. The after-effects were was commissioned to investigate mephedrone use in similar to speed come-downs, involving fatigue, Middlesbrough, and to produce a publication for local dizziness, and low mood. Most users regarded users. This research incorporated a literature review, mephedrone’s effects as superior to those of interviews with drugs workers, and focus groups cocaine and ecstasy. Few harmful consequences of with 10 users of mephedrone (nine men and one mephedrone use were reported, though participants woman, mostly young adults). All participants were had all been using for less than three months. No regular users of drugs - notably alcohol, cannabis participants felt they were dependent, though most and amphetamine, but also cocaine and ecstasy. All reported cravings and some were using nearly had begun using mephedrone one to three months every day. Some participants reported skin-rashes, ago, and most were aware that it was ‘legal’. About insomnia and/or amnesia following mephedrone use, half had been obtaining mephedrone from internet though none reported needing any medical or other companies (£10 per gram), and half from drug help. dealers in nightclubs (£15 per gram). All agreed that mephedrone had quickly become very popular in It is concluded that, on the basis of our current Middlesbrough, and was mainly used in nightclubs knowledge, the following harm-reduction advice and parties. Since sniffing it caused painful ‘nose should be given to mephedrone users: use burns’, most had switched to swallowing it. The occasionally (less than weekly); use moderately typical amount of mephedrone consumed over an (no more than 0.5g per session); swallow rather evening/night was about 0.5 to one gram, usually than sniff the powder; use at home, but if using in taken in doses (keys) of 100-200 mg every hour nightclubs stay close to friends; avoid mixing it with or two. Weekend use was the norm, though some alcohol, stimulants or prescribed medicines; buy it participants were near-daily users. Most participants from headshops/internet rather than drug dealers; reported ‘mixing’ alcohol and/or cannabis with and avoid mephedrone if you have health problems mephedrone, either to heighten the effects or (particularly mental disorders or heart problems). The ameliorate the come-down. main message is: look after your friends, and they will look after you. 3 1. Introduction contacted the Director of Communications (Mike Linnell) at Lifeline Publications & Research, to make arrangements for research into local mephedrone ‘Legal highs’ are drugs which are neither controlled use to be conducted. Staff at the agency then began by the 1971 Misuse of Drugs Act (MoDA), nor licensed asking service users who used mephedrone if they or for legal use (like alcohol and tobacco). Such drugs any of their associates would be willing to participate are legal to use and possess, and legal to supply in a focus group. The single criterion for inclusion as long as they are sold for purposes other than was that potential participants must have used or human consumption. If they are sold or advertised be using mephedrone. On Monday 14th December as drugs, they become subject to the 1968 Medicines 2009, two senior members of Lifeline Publications & Act – which has a maximum sentence of two years Research - Mike Linnell (ML) and Russell Newcombe imprisonment for unauthorised supply. The leaves and (RN) - visited the premises of Lifeline Middlesbrough stems of the shrub khat (qat) are traditionally chewed to conduct short unstructured interviews with two for their stimulant effects in East Africa and the members of staff, and focus groups with mephedrone Middle East, and are used as a natural ‘legal high’ by users. some communities in Britain. The active ingredients of khat are cathinone and cathine, stimulant drugs Focus groups. For practical reasons (time classified as keto-amphetamines. Over the past constraints and the staggered times of arrival of decade, enterprising ‘legal high’ producers have research participants) three focus groups were manufactured several synthetic cathinone realated conducted: one with six participants, and two drugs, the most well-known of which is mephedrone with two participants each – making a total of 10 (Meyer et al. 2009; Appendix 1). The full chemical mephedrone users. Each focus group was conducted name of mephedrone is 4-methylmethcathinone in a private room at Lifeline Middlesbrough, and (4MMC), known to users as m-cat or meph, and sold began with an introduction from ML, who explained from headshops under the trade name of Meow the purpose of the research (to produce a publication (or Miaow). It is not controlled in the UK, though for mephedrone users); who we were; and that is prohibited in Scandinavian countries and Israel. participation was voluntary, confidential and Though research has just begun, the effects of anonymous. mephedrone have been reported to resemble those of both speed (stimulant amphetamines) and ecstasy Using a pre-structured list of topics (Appendix 2), (hallucinogenic amphetamines). The nature and ML prompted participants to give information about extent of its harmful consequences has also not yet mephedrone use by them and their associates, and been researched. At the time of writing, there was RN kept a written record of their responses (as well just one published report of mephedrone poisoning as making some verbal prompts). Most participants in the UK (Wood et al. 2009), and just one death made useful contributions to the discussions, and linked to mephedrone reported by the mass media only two were relatively quiet (P3 and P9). At the end in Britain – a young man who committed suicide of each session, participants were asked if they had allegedly due to post-mephedrone depression (The any questions, thanked for their help, and given £20 Sun, 8th December 2009). each for their assistance. Each focus group lasted between 45 and 60 minutes. In December 2009, Lifeline Publications & Research was commissioned by Safer Middlesbrough Participants. All 10 participants were residents Partnership to conduct some research into of Middlesbrough, and over 18 years of age. The mephedrone, and to produce a publication for local participants within each focus group were friends users of mephedrone. This document reports the and/or associates (with one exception). Initial methods and findings of this research. discussions revealed that all participants were poly-drug users, and were mainly users of three recreational drugs: cannabis (especially skunk), 2. Research methods alcohol and amphetamine sulphate (speed or wiz). Most participants also mentioned being users of Overview. The research had three components: a cocaine (sniff) and ecstasy (pills) in the past, but review of the available literature, interviews with drug generally indicated that they had ceased or reduced agency staff, and focus groups with mephedrone their use of these two popular drugs because their users in Middlesbrough. At the start of December quality (purity) had dropped so much over the last 2009, the Manager of Lifeline Middlesbrough few years (confirmed by analyses of drugs seized 4 by the police, e.g. Home Office 2009). This partly was usually sought in such circumstances. In the explains their increased interest in ‘legal highs’ Findings section, no distinctions are made between such as keto-amphetamines. Many participants also the individual focus groups except when necessary. mentioned use of ketamine, and some mentioned use To indicate the extent of agreement on particular of other hallucinogens (e.g. LSD, magic mushrooms) issues, the following quantifiers are used: all (10), - but none indicated any use of heroin or crack. For most (7 to 9), around half (4 to 6), some (1 to 3), and instance, P2 stated that “we don’t touch smack, but none. ‘All or most’ will also be referred to as ‘general I’ve got a mate who does, and I’m OK with that as agreement’ or ‘consensus’.
Recommended publications
  • EL PASO INTELLIGENCE CENTER DRUG TREND Synthetic Stimulants Marketed As Bath Salts
    LAW ENFORCEMENT SENSITIVE EPIC Tactical Intelligence Bulletins EL PASO INTELLIGENCE CENTER DRUG TREND TACTICAL INTELLIGENCE BULLETIN EB11-16 ● Synthetic Stimulants Marketed as Bath Salts ● March 8, 2011 This document is the property of the Drug Enforcement Administration (DEA) and is marked Law Enforcement Sensitive (LES). Further dissemination of this document is strictly forbidden except to other law enforcement agencies for criminal law enforcement purposes. The following information must be handled and protected accordingly. Summary Across the United States, synthetic stimulants that are sold as “bath salts”¹ have become a serious drug abuse threat. These products are produced under a variety of faux brand names, and they are indirectly marketed as legal alternatives to cocaine, amphetamine, and Ecstasy (MDMA or 3,4-Methylenedioxymethamphetamine). Poison control centers nationwide have received hundreds of calls related to the side-effects of, and overdoses from, the use of these potent and unpredictable products. Numerous media reports have cited bath salt stimulant overdose incidents that have resulted in emergency room visits, hospitalizations, and severe psychotic episodes, some of which, have led to violent outbursts, self-inflicted wounds, and even suicides. A number of states have imposed emergency measures to ban bath salt stimulant products (or the chemicals in them) including Florida, Louisiana, North Dakota, and West Virginia; and similar measures are pending in Hawaii, Kentucky, Michigan, and Mississippi. A prominent U.S.
    [Show full text]
  • Mephedrone Is a Class B Drug, Which Means Self-Referral Form and It Is Illegal to Possess, Sell Or Give Away
    THE LAW CONTACT INFORMATION Novel Psychoacve Substances (NPS) are If you would like support controlled substances under the Misuse of around your substance HMP BRISTOL Drugs Act (1971). use, please complete a Substance Misuse Team Mephedrone is a Class B drug, which means self-referral form and it is illegal to possess, sell or give away. return to Health Care. Possession can result in prosecuon and up PALS to a five year prison sentence or an unlimited fine. To make a comment, raise a concern Mephedrone or make a complaint, please contact the Trust’s Paent Advice and Liaison Supplying someone else, even your friends, Service (PALS). can result in a prison sentence of up to 14 Know the effects years or an unlimited fine. Tel: 01249 468261 Freephone: 0800 073 1778 Email: [email protected] Being convicted of a drug‐related offence could have a serious impact on your future. This could affect the types of jobs you apply for and stop you from entering certain OTHER FORMATS OR countries. LANGUAGES If you need this informaon in other formats (such as large print, Braille) or in another language, please call PALS Lead: Chris Eade Leaflet code: 326 Approval date: Aug 2014 Review due: Aug 2017 WHAT IS MEPHEDRONE EFFECTS THE RISKS Mephedrone is also known as The effects of mephedrone can vary and All drugs pose a risk of dependency and meow meow, meph, m‐cat and miaow can affect people differently. It is never can cause short and long‐term damage certain what effect it will have on the user.
    [Show full text]
  • Subchronic Continuous Phencyclidine Administration Potentiates Amphetamine-Induced Frontal Cortex Dopamine Release
    Neuropsychopharmacology (2003) 28, 34–44 & 2003 Nature Publishing Group All rights reserved 0893-133X/03 $25.00 www.neuropsychopharmacology.org Subchronic Continuous Phencyclidine Administration Potentiates Amphetamine-Induced Frontal Cortex Dopamine Release Andrea Balla1, Henry Sershen1,2, Michael Serra1, Rajeth Koneru1 and Daniel C Javitt*,1,2 1 2 Nathan Kline Institute for Psychiatric Research, Orangeburg, NY, USA; Department of Psychiatry, New York University School of Medicine, New York, NY, USA Functional dopaminergic hyperactivity is a key feature of schizophrenia. Etiology of this dopaminergic hyperactivity, however, is unknown. We have recently demonstrated that subchronic phencyclidine (PCP) treatment in rodents induces striatal dopaminergic hyperactivity similar to that observed in schizophrenia. The present study investigates the ability of PCP to potentiate amphetamine-induced dopamine release in prefrontal cortex (PFC) and nucleus accumbens (NAc) shell. Prefrontal dopaminergic hyperactivity is postulated to underlie cognitive dysfunction in schizophrenia. In contrast, the degree of NAc involvement is unknown and recent studies have suggested that PCP-induced hyperactivity in rodents may correlate with PFC, rather than NAc, dopamine levels. Rats were treated with 5–20 mg/kg/day PCP for 3–14 days by osmotic minipump. PFC and NAc dopamine release to amphetamine challenge (1 mg/kg) was monitored by in vivo microdialysis and HPLC-EC. Doses of 10 mg/kg/day and above produced serum PCP concentrations (50–150 ng/ml) most associated with PCP psychosis in humans. PCP-treated rats showed significant, dose-dependent enhancement in amphetamine-induced dopamine release in PFC but not NAc, along with significantly enhanced locomotor activity. Enhanced response was observed following 3-day, as well as 14-day, treatment and resolved within 4 days of PCP treatment withdrawal.
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
    [Show full text]
  • Pharmacology and Toxicology of Amphetamine and Related Designer Drugs
    Pharmacology and Toxicology of Amphetamine and Related Designer Drugs U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES • Public Health Service • Alcohol Drug Abuse and Mental Health Administration Pharmacology and Toxicology of Amphetamine and Related Designer Drugs Editors: Khursheed Asghar, Ph.D. Division of Preclinical Research National Institute on Drug Abuse Errol De Souza, Ph.D. Addiction Research Center National Institute on Drug Abuse NIDA Research Monograph 94 1989 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Alcohol, Drug Abuse, and Mental Health Administration National Institute on Drug Abuse 5600 Fishers Lane Rockville, MD 20857 For sale by the Superintendent of Documents, U.S. Government Printing Office Washington, DC 20402 Pharmacology and Toxicology of Amphetamine and Related Designer Drugs ACKNOWLEDGMENT This monograph is based upon papers and discussion from a technical review on pharmacology and toxicology of amphetamine and related designer drugs that took place on August 2 through 4, 1988, in Bethesda, MD. The review meeting was sponsored by the Biomedical Branch, Division of Preclinical Research, and the Addiction Research Center, National Institute on Drug Abuse. COPYRIGHT STATUS The National Institute on Drug Abuse has obtained permission from the copyright holders to reproduce certain previously published material as noted in the text. Further reproduction of this copyrighted material is permitted only as part of a reprinting of the entire publication or chapter. For any other use, the copyright holder’s permission is required. All other matieral in this volume except quoted passages from copyrighted sources is in the public domain and may be used or reproduced without permission from the Institute or the authors.
    [Show full text]
  • Effects of Mephedrone and Amphetamine Exposure During Adolescence on Spatial Memory in Adulthood: Behavioral and Neurochemical Analysis
    International Journal of Molecular Sciences Article Effects of Mephedrone and Amphetamine Exposure during Adolescence on Spatial Memory in Adulthood: Behavioral and Neurochemical Analysis Pawel Grochecki 1, Irena Smaga 2 , Malgorzata Lopatynska-Mazurek 1, Ewa Gibula-Tarlowska 1, Ewa Kedzierska 1, Joanna Listos 1, Sylwia Talarek 1, Marta Marszalek-Grabska 3 , Magdalena Hubalewska-Mazgaj 2, Agnieszka Korga-Plewko 4 , Jaroslaw Dudka 5, Zbigniew Marzec 6, Małgorzata Filip 2 and Jolanta H. Kotlinska 1,* 1 Department of Pharmacology and Pharmacodynamics, Medical University, 20-093 Lublin, Poland; [email protected] (P.G.); [email protected] (M.L.-M.); [email protected] (E.G.-T.); [email protected] (E.K.); [email protected] (J.L.); [email protected] (S.T.) 2 Department of Drug Addiction Pharmacology, Polish Academy of Sciences, 31-343 Krakow, Poland; [email protected] (I.S.); [email protected] (M.H.-M.); mal.fi[email protected] (M.F.) 3 Department of Experimental and Clinical Pharmacology, Medical University, 20-090 Lublin, Poland; [email protected] 4 Independent Medical Biology Unit, Medical University, 20-090 Lublin, Poland; [email protected] 5 Department of Toxicology, Medical University, 20-090 Lublin, Poland; [email protected] 6 Department of Food and Nutrition, Medical University, 20-093 Lublin, Poland; [email protected] Citation: Grochecki, P.; Smaga, I.; * Correspondence: [email protected] Lopatynska-Mazurek, M.; Gibula-Tarlowska, E.; Kedzierska, E.; Abstract: A synthetic cathinone, mephedrone is widely abused by adolescents and young adults. Listos, J.; Talarek, S.; Despite its widespread use, little is known regarding its long-term effects on cognitive function.
    [Show full text]
  • Ring-Substituted Amphetamine Interactions with Neurotransmitter Receptor Binding Sites in Human Cortex
    208 NeuroscienceLetters, 95 (1988) 208-212 Elsevier Scientific Publishers Ireland Ltd. NSL O5736 Ring-substituted amphetamine interactions with neurotransmitter receptor binding sites in human cortex Pamela A. Pierce and Stephen J. Peroutka Deparmentsof Neurologyand Pharmacology, Stanford University Medical Center, StanJbrd,CA 94305 (U.S.A.) (Received 31 May 1988; Revised version received 11 August 1988; Accepted 12 August 1988) Key words.' Ring-substituted amphetamine; (_+)-3,4-Methylenedioxyamphetamine; ( +_)-3,4-Methylene- dioxyethamphetamine; (_+)-3,4-Methylenedioxymethamphetamine; Ecstasy; 4-Bromo-2,5- dimethoxyphenylisopropylamine binding site; Human cortical receptor The binding affinities of 3 ring-substituted amphetamine compounds were determined at 9 neurotrans- mitter binding sites in human cortex. (_+)-3,4-Methylenedioxyamphetamine (MDAk (_+)-3,4-methylene- dioxyethamphetamine (MDE), and (_+)-3,4-methylenedioxymethamphetamine (MDMA or 'Ecstasy') all display highest affinity (approximately 1 /tM) for the recently identified 'DOB binding site' labeled by ['TBr]R(-)4-bromo-2,5-dimethoxyphenylisopropylamine ([77Br]R(-)DOB). MDA displays moderate affinity (4-5/iM) for the 5-hydroxytryptaminetA (5-HTr^), 5-HT_D,and =,-adrenergic sites in human cor- tex. MDE and MDMA display lower affinity or are inactive at all other sites tested in the present study. These observations are discussed in relation to the novel psychoactive effects of the ring-substituted amphetamines. A series of ring-substituted amphetamine derivatives exist which are structurally related to both amphetamines and hallucinogens. However, drugs such as (+)-3,4- methylenedioxyamphetamine (MDA), (_+)-3,4-methylenedioxyethamphetamine (MDE), and (+)-3,4-methylenedioxymethamphetamine (MDMA or 'Ecstasy') ap- pear to produce unique psychoactive effects which are distinct from the effects of both amphetamines and hallucinogens [13, 15].
    [Show full text]
  • Stimulant and Related Medications: US Food and Drug
    Stimulant and Related Medications: U.S. Food and Drug Administration-Approved Indications and Dosages for Use in Adults The therapeutic dosing recommendations for stimulant and related medications are based on U.S. Food and Drug Administration (FDA)-approved product labeling. Nevertheless, the dosing regimen is adjusted according to a patient’s individual response to pharmacotherapy. The FDA-approved dosages and indications for the use of stimulant and related medications in adults are provided in this table. All medication doses listed are for oral administration. Information on the generic availability of the stimulant and related medications can be found by searching the Electronic Orange Book at https://www.accessdata.fda.gov/scripts/cder/ob/default.cfm on the FDA website. Generic Medication Indication Dosing Information Other Information Availability amphetamine/dextroamphetamine ADHD Initial dose: May increase daily dose by 5 mg at Yes mixed salts[1] 5 mg once or twice a day; weekly intervals until optimal response Maximum dose: 40 mg per day is achieved. Only in rare cases will it be necessary to exceed a total of 40 mg per day. amphetamine/dextroamphetamine narcolepsy Initial dose: 10 mg per day; May increase daily dose by 10 mg at Yes mixed salts Usual dose: weekly intervals until optimal response 5 mg to 60 mg per day is achieved. Take first dose in divided doses upon awakening. amphetamine/dextroamphetamine ADHD Recommended dose: Patients switching from regular-release Yes mixed salts ER*[2] 20 mg once a day amphetamine/dextroamphetamine mixed salts may take the same total daily dose once a day. armodafinil[3] narcolepsy Recommended dose: Take as a single dose in the morning.
    [Show full text]
  • Recommended Methods for the Identification and Analysis Of
    Vienna International Centre, P.O. Box 500, 1400 Vienna, Austria Tel: (+43-1) 26060-0, Fax: (+43-1) 26060-5866, www.unodc.org RECOMMENDED METHODS FOR THE IDENTIFICATION AND ANALYSIS OF AMPHETAMINE, METHAMPHETAMINE AND THEIR RING-SUBSTITUTED ANALOGUES IN SEIZED MATERIALS (revised and updated) MANUAL FOR USE BY NATIONAL DRUG TESTING LABORATORIES Laboratory and Scientific Section United Nations Office on Drugs and Crime Vienna RECOMMENDED METHODS FOR THE IDENTIFICATION AND ANALYSIS OF AMPHETAMINE, METHAMPHETAMINE AND THEIR RING-SUBSTITUTED ANALOGUES IN SEIZED MATERIALS (revised and updated) MANUAL FOR USE BY NATIONAL DRUG TESTING LABORATORIES UNITED NATIONS New York, 2006 Note Mention of company names and commercial products does not imply the endorse- ment of the United Nations. This publication has not been formally edited. ST/NAR/34 UNITED NATIONS PUBLICATION Sales No. E.06.XI.1 ISBN 92-1-148208-9 Acknowledgements UNODC’s Laboratory and Scientific Section wishes to express its thanks to the experts who participated in the Consultative Meeting on “The Review of Methods for the Identification and Analysis of Amphetamine-type Stimulants (ATS) and Their Ring-substituted Analogues in Seized Material” for their contribution to the contents of this manual. Ms. Rosa Alis Rodríguez, Laboratorio de Drogas y Sanidad de Baleares, Palma de Mallorca, Spain Dr. Hans Bergkvist, SKL—National Laboratory of Forensic Science, Linköping, Sweden Ms. Warank Boonchuay, Division of Narcotics Analysis, Department of Medical Sciences, Ministry of Public Health, Nonthaburi, Thailand Dr. Rainer Dahlenburg, Bundeskriminalamt/KT34, Wiesbaden, Germany Mr. Adrian V. Kemmenoe, The Forensic Science Service, Birmingham Laboratory, Birmingham, United Kingdom Dr. Tohru Kishi, National Research Institute of Police Science, Chiba, Japan Dr.
    [Show full text]
  • Drugs of Abuseon September Archived 13-10048 No
    U.S. DEPARTMENT OF JUSTICE DRUG ENFORCEMENT ADMINISTRATION WWW.DEA.GOV 9, 2014 on September archived 13-10048 No. v. Stewart, in U.S. cited Drugs of2011 Abuse EDITION A DEA RESOURCE GUIDE V. Narcotics WHAT ARE NARCOTICS? Also known as “opioids,” the term "narcotic" comes from the Greek word for “stupor” and originally referred to a variety of substances that dulled the senses and relieved pain. Though some people still refer to all drugs as “narcot- ics,” today “narcotic” refers to opium, opium derivatives, and their semi-synthetic substitutes. A more current term for these drugs, with less uncertainty regarding its meaning, is “opioid.” Examples include the illicit drug heroin and pharmaceutical drugs like OxyContin®, Vicodin®, codeine, morphine, methadone and fentanyl. WHAT IS THEIR ORIGIN? The poppy papaver somniferum is the source for all natural opioids, whereas synthetic opioids are made entirely in a lab and include meperidine, fentanyl, and methadone. Semi-synthetic opioids are synthesized from naturally occurring opium products, such as morphine and codeine, and include heroin, oxycodone, hydrocodone, and hydromorphone. Teens can obtain narcotics from friends, family members, medicine cabinets, pharmacies, nursing 2014 homes, hospitals, hospices, doctors, and the Internet. 9, on September archived 13-10048 No. v. Stewart, in U.S. cited What are common street names? Street names for various narcotics/opioids include: ➔ Hillbilly Heroin, Lean or Purple Drank, OC, Ox, Oxy, Oxycotton, Sippin Syrup What are their forms? Narcotics/opioids come in various forms including: ➔ T ablets, capsules, skin patches, powder, chunks in varying colors (from white to shades of brown and black), liquid form for oral use and injection, syrups, suppositories, lollipops How are they abused? ➔ Narcotics/opioids can be swallowed, smoked, sniffed, or injected.
    [Show full text]
  • AGENDA Friday, September 9, 2016 7:00 A.M
    Needham Board of Health AGENDA Friday, September 9, 2016 7:00 a.m. – 9:00 a.m. Charles River Room – Public Services Administration Building 500 Dedham Avenue, Needham MA 02492 • 7:00 to 7:05 - Welcome & Review of Minutes (July 29 & August 29) • 7:05 to 7:30 - Director and Staff Reports (July & August) • 7:30 to 7:45 - Discussion about Proposed Plastic Bag Ban Christopher Thomas, Needham Resident • 7:45 to 7:50 - Off-Street Drainage Bond Discussion & Vote • 7:50 to 8:00 - Update on Wingate Pool Variance Application * * * * * * * * * * * * * Board of Health Public Hearing • 8:00 to 8:40 - Hearing for Proposed New or Amended BOH Regulations o Body Art o Synthetic Marijuana o Drug Paraphernalia • 8:40 to 8:50 - Board Discussion of Policy Positions • Other Items (Healthy Aging, Water Quality) • Next Meeting Scheduled for Friday October 14, 2016 • Adjournment (Please note that all times are approximate) 1471 Highland Avenue, Needham, MA 02492 781-455-7500 ext 511 (tel); 781-455-0892 (fax) E-mail: [email protected] Web: www.needhamma.gov/health NEEDHAM BOARD OF HEALTH July 29, 2016 MEETING MINUTES PRESENT: Edward V. Cosgrove, PhD, Chair, Jane Fogg, Vice-Chair, M.D., and Stephen Epstein, M.D STAFF: Timothy McDonald, Director, Donna Carmichael, Catherine Delano, Maryanne Dinell, Tara Gurge GUEST: Kevin Mulkern, Aquaknot Pools, Inc., Keith Mulkern, Aquaknot Pools, Inc., David Friedman, Wingate, Paul Humphreys, Michael Tomasello, Callahan, Inc. CONVENE: 7:00 a.m. – Public Services Administration Building (PSAB), 500 Dedham Avenue, Needham MA 02492 DISCUSSION: Call To Order – 7:06 a.m. – Dr. Cosgrove, Chairman APPROVE MINUTES: Upon motion duly made and seconded, the minutes of the BOH meeting of June 17, 2016 were approved as submitted.
    [Show full text]
  • Introduced B.,Byhansen, 16
    LB301 LB301 2021 2021 LEGISLATURE OF NEBRASKA ONE HUNDRED SEVENTH LEGISLATURE FIRST SESSION LEGISLATIVE BILL 301 Introduced by Hansen, B., 16. Read first time January 12, 2021 Committee: Judiciary 1 A BILL FOR AN ACT relating to the Uniform Controlled Substances Act; to 2 amend sections 28-401, 28-405, and 28-416, Revised Statutes 3 Cumulative Supplement, 2020; to redefine terms; to change drug 4 schedules and adopt federal drug provisions; to change a penalty 5 provision; and to repeal the original sections. 6 Be it enacted by the people of the State of Nebraska, -1- LB301 LB301 2021 2021 1 Section 1. Section 28-401, Revised Statutes Cumulative Supplement, 2 2020, is amended to read: 3 28-401 As used in the Uniform Controlled Substances Act, unless the 4 context otherwise requires: 5 (1) Administer means to directly apply a controlled substance by 6 injection, inhalation, ingestion, or any other means to the body of a 7 patient or research subject; 8 (2) Agent means an authorized person who acts on behalf of or at the 9 direction of another person but does not include a common or contract 10 carrier, public warehouse keeper, or employee of a carrier or warehouse 11 keeper; 12 (3) Administration means the Drug Enforcement Administration of the 13 United States Department of Justice; 14 (4) Controlled substance means a drug, biological, substance, or 15 immediate precursor in Schedules I through V of section 28-405. 16 Controlled substance does not include distilled spirits, wine, malt 17 beverages, tobacco, hemp, or any nonnarcotic substance if such substance 18 may, under the Federal Food, Drug, and Cosmetic Act, 21 U.S.C.
    [Show full text]